_id
695fba19c2e91020a7bd4308
Ticker
0JBU.LSE
Name
Intellia Therapeutics, Inc.
Exchange
LSE
Address
40 Erie Street, Cambridge, MA, United States, 02139
Country
UK
Sector
Industry
Currency
USD
Website
https://www.intelliatx.com
Description
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Last Close
10.35
Volume
319
Current Price
10.555
Change
0.45
Last Updated
2026-01-08T14:07:20.993Z
Ipo Date
-
Market Cap
45725657600
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
13782000
Cost Of Revenue
78949000
Gross Profit
-65167000
Operating Expenses
46310000
Operating Income
-111477000
Interest Expense
-
Pretax Income
-101324000
Net Income
-101324000
Eps
-0.9195556684938468
Dividends Per Share
-
Shares Outstanding
43419300
Income Tax Expense
-
EBITDA
-96388000
Operating Margin
-808.859381802351
Total Other Income Expense Net
10153000
Cash
193389000
Short Term Investments
317655000
Receivables
11050000
Inventories
-
Total Current Assets
581941000
Property Plant Equipment
138304000
Total Assets
925275000
Payables
13260000
Short Term Debt
27378000
Long Term Debt
-
Total Liabilities
176853000
Equity
748422000
Bs_currency_symbol
-
Depreciation
4936000
Change In Working Capital
4409000
Cash From Operations
-76899000
Capital Expenditures
29000
Cash From Investing
-741000
Cash From Financing
114857000
Net Change In Cash
37217000
Cf_currency_symbol
-
PE
-
PB
1.5539820315276673
ROE
-13.53835135792374
ROA
-10.950690335305719
FCF
-76928000
Fcf Percent
-5.58177332752866
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
13782000
Quarters > 0 > income Statement > cost Of Revenue
78949000
Quarters > 0 > income Statement > gross Profit
-65167000
Quarters > 0 > income Statement > operating Expenses
46310000
Quarters > 0 > income Statement > operating Income
-111477000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-101324000
Quarters > 0 > income Statement > net Income
-101324000
Quarters > 0 > income Statement > eps
-0.9195556684938468
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
110188000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-96388000
Quarters > 0 > income Statement > operating Margin
-808.859381802351
Quarters > 0 > income Statement > total Other Income Expense Net
10153000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
193389000
Quarters > 0 > balance Sheet > short Term Investments
317655000
Quarters > 0 > balance Sheet > receivables
11050000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
581941000
Quarters > 0 > balance Sheet > property Plant Equipment
138304000
Quarters > 0 > balance Sheet > total Assets
925275000
Quarters > 0 > balance Sheet > payables
13260000
Quarters > 0 > balance Sheet > short Term Debt
27378000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
176853000
Quarters > 0 > balance Sheet > equity
748422000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-101324000
Quarters > 0 > cash Flow > depreciation
4936000
Quarters > 0 > cash Flow > change In Working Capital
4409000
Quarters > 0 > cash Flow > cash From Operations
-76899000
Quarters > 0 > cash Flow > capital Expenditures
29000
Quarters > 0 > cash Flow > cash From Investing
-741000
Quarters > 0 > cash Flow > cash From Financing
114857000
Quarters > 0 > cash Flow > net Change In Cash
37217000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.9195556684938468
Quarters > 0 > ratios > PB
1.5539820315276673
Quarters > 0 > ratios > ROE
-13.53835135792374
Quarters > 0 > ratios > ROA
-10.950690335305719
Quarters > 0 > ratios > FCF
-76928000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-5.58177332752866
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
14245000
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
14245000
Quarters > 1 > income Statement > operating Expenses
124241000
Quarters > 1 > income Statement > operating Income
-109996000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-101255000
Quarters > 1 > income Statement > net Income
-101255000
Quarters > 1 > income Statement > eps
-0.9761211583696449
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
103732000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-107522000
Quarters > 1 > income Statement > operating Margin
-772.1726921726922
Quarters > 1 > income Statement > total Other Income Expense Net
8741000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
156172000
Quarters > 1 > balance Sheet > short Term Investments
303479000
Quarters > 1 > balance Sheet > receivables
11353000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
495945000
Quarters > 1 > balance Sheet > property Plant Equipment
188680000
Quarters > 1 > balance Sheet > total Assets
898894000
Quarters > 1 > balance Sheet > payables
9802000
Quarters > 1 > balance Sheet > short Term Debt
26990000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
183639000
Quarters > 1 > balance Sheet > equity
715255000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-101255000
Quarters > 1 > cash Flow > depreciation
2474000
Quarters > 1 > cash Flow > change In Working Capital
-19871000
Quarters > 1 > cash Flow > cash From Operations
-99622000
Quarters > 1 > cash Flow > capital Expenditures
239000
Quarters > 1 > cash Flow > cash From Investing
106910000
Quarters > 1 > cash Flow > cash From Financing
14652000
Quarters > 1 > cash Flow > net Change In Cash
21940000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.9761211583696449
Quarters > 1 > ratios > PB
1.5307705084200738
Quarters > 1 > ratios > ROE
-14.156489643553696
Quarters > 1 > ratios > ROA
-11.264398249404268
Quarters > 1 > ratios > FCF
-99861000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-7.01024921024921
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
16627000
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
16627000
Quarters > 2 > income Statement > operating Expenses
137434000
Quarters > 2 > income Statement > operating Income
-120807000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-114329000
Quarters > 2 > income Statement > net Income
-114329000
Quarters > 2 > income Statement > eps
-1.1046280193236715
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
103500000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-118309000
Quarters > 2 > income Statement > operating Margin
-726.5712395501292
Quarters > 2 > income Statement > total Other Income Expense Net
6478000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
126880000
Quarters > 2 > balance Sheet > short Term Investments
376867000
Quarters > 2 > balance Sheet > receivables
10504000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
551392000
Quarters > 2 > balance Sheet > property Plant Equipment
189906000
Quarters > 2 > balance Sheet > total Assets
986163000
Quarters > 2 > balance Sheet > payables
12364000
Quarters > 2 > balance Sheet > short Term Debt
38763000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
206244000
Quarters > 2 > balance Sheet > equity
779919000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-114329000
Quarters > 2 > cash Flow > depreciation
2498000
Quarters > 2 > cash Flow > change In Working Capital
-58784000
Quarters > 2 > cash Flow > cash From Operations
-148930000
Quarters > 2 > cash Flow > capital Expenditures
735000
Quarters > 2 > cash Flow > cash From Investing
94328000
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-54602000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-1.1046280193236715
Quarters > 2 > ratios > PB
1.400712766325734
Quarters > 2 > ratios > ROE
-14.659086392304843
Quarters > 2 > ratios > ROA
-11.593316723503113
Quarters > 2 > ratios > FCF
-149665000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-9.001323149094846
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
12874000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
12874000
Quarters > 3 > income Statement > operating Expenses
149321000
Quarters > 3 > income Statement > operating Income
-136447000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-128898000
Quarters > 3 > income Statement > net Income
-128898000
Quarters > 3 > income Statement > eps
-1.2655048843944823
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
101855000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-133881000
Quarters > 3 > income Statement > operating Margin
-1059.8648438713687
Quarters > 3 > income Statement > total Other Income Expense Net
7549000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
189182000
Quarters > 3 > balance Sheet > short Term Investments
412333000
Quarters > 3 > balance Sheet > receivables
8517000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
639863000
Quarters > 3 > balance Sheet > property Plant Equipment
246673000
Quarters > 3 > balance Sheet > total Assets
1191015000
Quarters > 3 > balance Sheet > payables
14589000
Quarters > 3 > balance Sheet > short Term Debt
20246000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
319059000
Quarters > 3 > balance Sheet > equity
871956000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-128898000
Quarters > 3 > cash Flow > depreciation
2566000
Quarters > 3 > cash Flow > change In Working Capital
2040000
Quarters > 3 > cash Flow > cash From Operations
-85195000
Quarters > 3 > cash Flow > capital Expenditures
981000
Quarters > 3 > cash Flow > cash From Investing
151565000
Quarters > 3 > cash Flow > cash From Financing
2317000
Quarters > 3 > cash Flow > net Change In Cash
68687000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.2655048843944823
Quarters > 3 > ratios > PB
1.232951576685062
Quarters > 3 > ratios > ROE
-14.782626646298667
Quarters > 3 > ratios > ROA
-10.822533721237768
Quarters > 3 > ratios > FCF
-86176000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-6.693801460307597
Quarters > 3 > health Score
35
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
57877000
Annuals > 0 > income Statement > cost Of Revenue
10285000
Annuals > 0 > income Statement > gross Profit
47592000
Annuals > 0 > income Statement > operating Expenses
581855000
Annuals > 0 > income Statement > operating Income
-534263000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-519021000
Annuals > 0 > income Statement > net Income
-519021000
Annuals > 0 > income Statement > eps
-5.250644923064472
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
98849000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-523978000
Annuals > 0 > income Statement > operating Margin
-923.100713582252
Annuals > 0 > income Statement > total Other Income Expense Net
15242000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
189182000
Annuals > 0 > balance Sheet > short Term Investments
412333000
Annuals > 0 > balance Sheet > receivables
8517000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
639863000
Annuals > 0 > balance Sheet > property Plant Equipment
246673000
Annuals > 0 > balance Sheet > total Assets
1191015000
Annuals > 0 > balance Sheet > payables
14589000
Annuals > 0 > balance Sheet > short Term Debt
20246000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
319059000
Annuals > 0 > balance Sheet > equity
871956000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-519021000
Annuals > 0 > cash Flow > depreciation
10285000
Annuals > 0 > cash Flow > change In Working Capital
11878000
Annuals > 0 > cash Flow > cash From Operations
-348880000
Annuals > 0 > cash Flow > capital Expenditures
5778000
Annuals > 0 > cash Flow > cash From Investing
125567000
Annuals > 0 > cash Flow > cash From Financing
185747000
Annuals > 0 > cash Flow > net Change In Cash
-37566000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-5.250644923064472
Annuals > 0 > ratios > PB
1.1965640410754672
Annuals > 0 > ratios > ROE
-59.52376037322984
Annuals > 0 > ratios > ROA
-43.57804057883402
Annuals > 0 > ratios > FCF
-354658000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-6.127788240579159
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
36275000
Annuals > 1 > income Statement > cost Of Revenue
8976000
Annuals > 1 > income Statement > gross Profit
27299000
Annuals > 1 > income Statement > operating Expenses
542590000
Annuals > 1 > income Statement > operating Income
-515291000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-481192000
Annuals > 1 > income Statement > net Income
-481192000
Annuals > 1 > income Statement > eps
-5.420660132927791
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
88770000
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-506315000
Annuals > 1 > income Statement > operating Margin
-1420.5127498277052
Annuals > 1 > income Statement > total Other Income Expense Net
34099000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
226748000
Annuals > 1 > balance Sheet > short Term Investments
685475000
Annuals > 1 > balance Sheet > receivables
36456000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
998330000
Annuals > 1 > balance Sheet > property Plant Equipment
148135000
Annuals > 1 > balance Sheet > total Assets
1300977000
Annuals > 1 > balance Sheet > payables
7452000
Annuals > 1 > balance Sheet > short Term Debt
18599000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
250808000
Annuals > 1 > balance Sheet > equity
1050169000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-481192000
Annuals > 1 > cash Flow > depreciation
8976000
Annuals > 1 > cash Flow > change In Working Capital
-52452000
Annuals > 1 > cash Flow > cash From Operations
-394086000
Annuals > 1 > cash Flow > capital Expenditures
13985000
Annuals > 1 > cash Flow > cash From Investing
-31347000
Annuals > 1 > cash Flow > cash From Financing
130323000
Annuals > 1 > cash Flow > net Change In Cash
-295110000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-5.420660132927791
Annuals > 1 > ratios > PB
0.8922062544219073
Annuals > 1 > ratios > ROE
-45.82043461576185
Annuals > 1 > ratios > ROA
-36.986972098661234
Annuals > 1 > ratios > FCF
-408071000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-11.249372846312887
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
52121000
Annuals > 2 > income Statement > cost Of Revenue
7572000
Annuals > 2 > income Statement > gross Profit
44549000
Annuals > 2 > income Statement > operating Expenses
502713000
Annuals > 2 > income Statement > operating Income
-458164000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-474186000
Annuals > 2 > income Statement > net Income
-474186000
Annuals > 2 > income Statement > eps
-6.160499922049577
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
76972000
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-450592000
Annuals > 2 > income Statement > operating Margin
-879.0391588802978
Annuals > 2 > income Statement > total Other Income Expense Net
-16022000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
523506000
Annuals > 2 > balance Sheet > short Term Investments
669116000
Annuals > 2 > balance Sheet > receivables
3768000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
1216797000
Annuals > 2 > balance Sheet > property Plant Equipment
160997000
Annuals > 2 > balance Sheet > total Assets
1520114000
Annuals > 2 > balance Sheet > payables
5154000
Annuals > 2 > balance Sheet > short Term Debt
16685000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
284530000
Annuals > 2 > balance Sheet > equity
1235584000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-474186000
Annuals > 2 > cash Flow > depreciation
7572000
Annuals > 2 > cash Flow > change In Working Capital
-53873000
Annuals > 2 > cash Flow > cash From Operations
-333287000
Annuals > 2 > cash Flow > capital Expenditures
58390000
Annuals > 2 > cash Flow > cash From Investing
160309000
Annuals > 2 > cash Flow > cash From Financing
582955000
Annuals > 2 > cash Flow > net Change In Cash
409977000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-6.160499922049577
Annuals > 2 > ratios > PB
0.6575347851704134
Annuals > 2 > ratios > ROE
-38.37747979902621
Annuals > 2 > ratios > ROA
-31.194107810335275
Annuals > 2 > ratios > FCF
-391677000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-7.514763722875617
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
33053000
Annuals > 3 > income Statement > cost Of Revenue
6891000
Annuals > 3 > income Statement > gross Profit
26162000
Annuals > 3 > income Statement > operating Expenses
294012000
Annuals > 3 > income Statement > operating Income
-267850000
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-267892000
Annuals > 3 > income Statement > net Income
-267892000
Annuals > 3 > income Statement > eps
-3.778768301971958
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
70894000
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-260959000
Annuals > 3 > income Statement > operating Margin
-810.3651710888572
Annuals > 3 > income Statement > total Other Income Expense Net
-42000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
123406000
Annuals > 3 > balance Sheet > short Term Investments
625282000
Annuals > 3 > balance Sheet > receivables
2031000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
769303000
Annuals > 3 > balance Sheet > property Plant Equipment
100111000
Annuals > 3 > balance Sheet > total Assets
1294464000
Annuals > 3 > balance Sheet > payables
9653000
Annuals > 3 > balance Sheet > short Term Debt
9112000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
254220000
Annuals > 3 > balance Sheet > equity
1040244000
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-267892000
Annuals > 3 > cash Flow > depreciation
6891000
Annuals > 3 > cash Flow > change In Working Capital
-22904000
Annuals > 3 > cash Flow > cash From Operations
-225030000
Annuals > 3 > cash Flow > capital Expenditures
12756000
Annuals > 3 > cash Flow > cash From Investing
-550778000
Annuals > 3 > cash Flow > cash From Financing
736688000
Annuals > 3 > cash Flow > net Change In Cash
-39120000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-3.778768301971958
Annuals > 3 > ratios > PB
0.7193371651266433
Annuals > 3 > ratios > ROE
-25.752804149795626
Annuals > 3 > ratios > ROA
-20.695206664689014
Annuals > 3 > ratios > FCF
-237786000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-7.194082231567482
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.9195556684938468
Valuation > metrics > PB
1.5539820315276673
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-13.53835135792374
Profitability > metrics > ROA
-17.411387065011745
Profitability > metrics > Net Margin
-7.351908286170367
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.23630117767783415
Risk > metrics > Interest Coverage
-22.584481361426256
Risk > final Score
-30
Risk > verdict
High
Liquidity > metrics > Current Ratio
14.320119100349427
Liquidity > metrics > Quick Ratio
14.320119100349427
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-10
Prev Risks > 1
-61
Prev Risks > 2
-50
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:13:48.520Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-0.97
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Intellia Therapeutics, Inc.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.97
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.